Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.03 Insider Own4.40% Shs Outstand77.97M Perf Week2.97%
Market Cap12.05B Forward P/E- EPS next Y-3.00 Insider Trans-5.29% Shs Float73.57M Perf Month-6.28%
Income-530.30M PEG- EPS next Q-1.62 Inst Own95.20% Short Float14.19% Perf Quarter25.15%
Sales450.20M P/S26.76 EPS this Y-77.80% Inst Trans0.20% Short Ratio12.24 Perf Half Y27.17%
Book/sh13.38 P/B11.88 EPS next Y44.00% ROA-22.70% Target Price194.15 Perf Year28.65%
Cash/sh27.21 P/C5.84 EPS next 5Y-0.20% ROE-53.00% 52W Range72.05 - 175.00 Perf YTD23.22%
Dividend- P/FCF51.48 EPS past 5Y-23.40% ROI-47.10% 52W High-9.61% Beta1.95
Dividend %- Quick Ratio6.40 Sales past 5Y108.10% Gross Margin87.90% 52W Low119.54% ATR5.72
Employees743 Current Ratio6.90 Sales Q/Q45.10% Oper. Margin- RSI (14)47.33 Volatility2.91% 3.62%
OptionableYes Debt/Eq0.67 EPS Q/Q48.20% Profit Margin- Rel Volume0.12 Prev Close159.00
ShortableYes LT Debt/Eq0.67 EarningsAug 05 AMC Payout- Avg Volume852.82K Price158.18
Recom1.70 SMA20-0.70% SMA50-2.02% SMA20024.27% Volume8,196 Change-0.52%
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Aug-11-20 10:19AM  
Aug-06-20 10:54AM  
Aug-05-20 06:05PM  
Jul-31-20 06:15PM  
Jul-29-20 12:33PM  
Jul-24-20 01:59PM  
Jul-15-20 08:30AM  
Jul-10-20 08:47PM  
Jul-02-20 08:21AM  
Jun-30-20 06:15PM  
Jun-29-20 10:06AM  
Jun-26-20 08:30AM  
Jun-23-20 04:05PM  
Jun-22-20 08:00AM  
Jun-18-20 08:30AM  
Jun-16-20 12:00PM  
Jun-15-20 04:02PM  
Jun-09-20 10:34AM  
Jun-08-20 04:15PM  
Jun-05-20 04:05PM  
Jun-02-20 08:57PM  
May-29-20 06:28PM  
May-28-20 11:30AM  
May-18-20 11:38AM  
May-15-20 04:15PM  
May-14-20 10:53AM  
May-13-20 02:56PM  
May-12-20 04:30PM  
May-11-20 07:00AM  
May-07-20 11:41AM  
May-06-20 06:15PM  
Apr-30-20 06:52PM  
Apr-29-20 08:30AM  
Apr-28-20 08:30AM  
Apr-15-20 08:34AM  
Apr-14-20 07:29AM  
Apr-08-20 02:19PM  
Mar-31-20 06:06PM  
Mar-27-20 11:31AM  
Mar-24-20 02:20AM  
Mar-11-20 07:57PM  
Feb-28-20 06:20PM  
Feb-27-20 10:47AM  
Feb-26-20 06:15PM  
Feb-19-20 12:31PM  
Feb-18-20 08:33AM  
Feb-10-20 02:09PM  
Feb-04-20 11:28AM  
Feb-03-20 03:31AM  
Jan-31-20 06:16PM  
Jan-30-20 07:19AM  
Jan-28-20 02:36PM  
Jan-23-20 05:15PM  
Jan-22-20 11:48AM  
Jan-20-20 08:54AM  
Jan-16-20 01:10PM  
Jan-13-20 01:56PM  
Jan-10-20 10:08AM  
Jan-09-20 09:12PM  
Jan-06-20 08:30AM  
Dec-31-19 06:06PM  
Dec-26-19 11:10AM  
Dec-24-19 12:15PM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wigzell Hans Lennart RudolfDirectorAug 10Option Exercise34.9210,000349,20023,792Aug 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 10Sale159.0010,0001,590,04413,792Aug 11 08:00 PM
Barry RichardDirectorAug 07Sale158.5030,0004,754,9723,129,140Aug 07 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Option Exercise29.601,12533,3008,957Aug 05 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Sale155.001,125174,3757,832Aug 05 08:00 PM
Mahatme SandeshEVP, CFO & CBOJul 08Option Exercise19.693,80674,94120,260Jul 09 08:00 PM
Howton David TEVP, General CounselJun 22Option Exercise25.76105,1222,708,440136,993Jun 22 09:17 PM
Howton David TEVP, General CounselJun 22Sale170.88105,12217,962,83131,871Jun 22 09:17 PM
Wigzell Hans Lennart RudolfDirectorMay 20Option Exercise10.085,00050,40018,792May 22 08:00 PM
Wigzell Hans Lennart RudolfDirectorMay 20Sale150.645,000753,21013,792May 22 08:00 PM
Barry RichardDirectorMay 15Sale141.2630,0004,237,9463,159,140May 15 09:02 PM
Wigzell Hans Lennart RudolfDirectorMar 04Option Exercise8.465,00042,30018,792Mar 06 08:01 PM
Wigzell Hans Lennart RudolfDirectorMar 04Sale116.895,000584,45013,792Mar 06 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Option Exercise28.88125,0003,610,443155,179Dec 17 08:00 PM
Howton David TEVP, General CounselDec 13Option Exercise21.4878,0001,675,439103,171Dec 17 08:01 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Option Exercise23.7032,706775,23243,867Dec 17 08:02 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Sale125.5042,0005,271,0001,867Dec 17 08:02 PM
Howton David TEVP, General CounselDec 13Sale125.5078,0009,789,00025,171Dec 17 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Sale125.50125,00015,687,50030,179Dec 17 08:00 PM
Howton David TEVP, General CounselNov 22Option Exercise16.1334,272552,66736,993Nov 26 08:01 PM
Howton David TEVP, General CounselNov 22Sale105.0025,0002,625,00011,993Nov 26 08:01 PM
Barry RichardDirectorSep 13Buy87.493,309289,5043,187,065Sep 16 08:00 AM
Barry RichardDirectorSep 12Buy87.491,691147,9503,183,756Sep 16 08:00 AM
BONNEY MICHAEL WDirectorSep 09Buy86.742,000173,4807,051Sep 09 02:18 PM
BEHRENS M KATHLEENDirectorSep 06Buy87.982,500219,950125,667Sep 06 02:13 PM
BEHRENS M KATHLEENDirectorSep 05Option Exercise7.805,00039,000123,167Sep 06 02:13 PM
Mahatme SandeshEVP, CFO & CBOAug 21Option Exercise23.85100,0002,385,000130,179Aug 22 07:20 PM
Barry RichardDirectorAug 20Buy99.325,000496,5933,182,065Aug 20 05:43 PM
Mahatme SandeshEVP, CFO & CBOAug 15Option Exercise24.739,754241,23230,179Aug 15 04:33 PM